NO982006L - Terapeutisk preparat for transdermal tilf°rsel av virksomme stoffer gjennom huden - Google Patents

Terapeutisk preparat for transdermal tilf°rsel av virksomme stoffer gjennom huden

Info

Publication number
NO982006L
NO982006L NO982006A NO982006A NO982006L NO 982006 L NO982006 L NO 982006L NO 982006 A NO982006 A NO 982006A NO 982006 A NO982006 A NO 982006A NO 982006 L NO982006 L NO 982006L
Authority
NO
Norway
Prior art keywords
skin
active substances
transdermal delivery
therapeutic preparation
transdermal
Prior art date
Application number
NO982006A
Other languages
English (en)
Other versions
NO982006D0 (no
Inventor
Bodo Asmussen
Andreas Koch
Rudolf Matusch
Original Assignee
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohmann Therapie Syst Lts filed Critical Lohmann Therapie Syst Lts
Publication of NO982006L publication Critical patent/NO982006L/no
Publication of NO982006D0 publication Critical patent/NO982006D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det er beskrevet et terapeutisk preparat for transdermal tilførsel av virksomme stoffer gjennom huden, inneholdende tilsatser som bevirker en økning av den perkutane absorpsjonsraten av transdermalt, normalt bare utilstrekkelig resorberbare virkestoffer, kjennetegnet ved at tilsatsene er HMG-CoA-reduktase-inhibitorer.
NO982006A 1995-11-06 1998-05-04 Terapeutisk preparat for transdermal tilf÷rsel av virksomme stoffer gjennom huden NO982006D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19541260A DE19541260A1 (de) 1995-11-06 1995-11-06 Therapeutische Zubereitung zur transdermalen Applikation von Wirkstoffen durch die Haut
PCT/EP1996/004138 WO1997017061A1 (de) 1995-11-06 1996-09-21 Therapeutische zubereitung zur transdermalen applikation von wirkstoffen durch die haut

Publications (2)

Publication Number Publication Date
NO982006L true NO982006L (no) 1998-05-04
NO982006D0 NO982006D0 (no) 1998-05-04

Family

ID=7776710

Family Applications (1)

Application Number Title Priority Date Filing Date
NO982006A NO982006D0 (no) 1995-11-06 1998-05-04 Terapeutisk preparat for transdermal tilf÷rsel av virksomme stoffer gjennom huden

Country Status (21)

Country Link
US (1) US6379696B1 (no)
EP (1) EP0859595B1 (no)
JP (1) JP2001507331A (no)
KR (1) KR100445940B1 (no)
CN (1) CN1201385A (no)
AT (1) ATE186209T1 (no)
AU (1) AU716896B2 (no)
CZ (1) CZ289143B6 (no)
DE (2) DE19541260A1 (no)
ES (1) ES2141534T3 (no)
GR (1) GR3032523T3 (no)
IL (1) IL124279A (no)
MX (1) MX9803563A (no)
MY (1) MY132407A (no)
NO (1) NO982006D0 (no)
NZ (1) NZ318783A (no)
PL (1) PL326497A1 (no)
PT (1) PT859595E (no)
SK (1) SK281405B6 (no)
WO (1) WO1997017061A1 (no)
ZA (1) ZA969271B (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19830732B4 (de) * 1998-07-09 2008-11-13 Lts Lohmann Therapie-Systeme Ag Zusammensetzung, enthaltend mindestens einen die Blutfettwerte beeinflussenden Wirkstoff und seine Verwendung
JP5507030B2 (ja) * 2000-09-08 2014-05-28 アルザ・コーポレーシヨン 経路閉鎖を阻害することによる経皮的薬物流動の減少の抑制方法
US20020187169A1 (en) * 2001-05-11 2002-12-12 Shoujun Chen Kavalactone compositions
CA2534238A1 (en) * 2003-07-28 2005-02-10 Alza Corporation Transdermal warfarin-containing delivery system
US20070166360A1 (en) * 2004-03-31 2007-07-19 Kowa Co., Ltd. External preparation
US9597289B2 (en) * 2006-04-26 2017-03-21 Rosemont Pharmaceuticals Ltd. Liquid oral simvastatin compositions
US7803778B2 (en) 2006-05-23 2010-09-28 Theracos, Inc. Glucose transport inhibitors and methods of use
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
US7652767B2 (en) * 2006-10-19 2010-01-26 Sporian Microsystems, Inc. Optical sensor with chemically reactive surface
US20080152592A1 (en) * 2006-12-21 2008-06-26 Bayer Healthcare Llc Method of therapeutic drug monitoring
WO2008115224A2 (en) * 2007-03-20 2008-09-25 Bayer Healthcare Llc Method of analyzing an analyte
JP5583003B2 (ja) 2007-04-02 2014-09-03 セラコス・インコーポレイテッド ベンジルグルコシド誘導体およびその用途
NZ583369A (en) 2007-08-23 2011-08-26 Theracos Inc Benzylbenzene derivatives and methods of use
AU2009270936B2 (en) 2008-07-15 2014-12-18 Theracos, Inc. Deuterated benzylbenzene derivatives and methods of use
CN103910702A (zh) 2008-08-22 2014-07-09 泰拉科斯有限公司 制备sglt2抑制剂的方法
WO2010068483A2 (en) 2008-11-25 2010-06-17 University Of Rochester Mlk inhibitors and methods of use
CA2764526A1 (en) 2009-06-24 2010-12-29 Christine Kritikou The use of spinosyns and spinosyn compositions against diseases caused by protozoans, viral infections and cancer
WO2011130455A1 (en) 2010-04-13 2011-10-20 Najib Babul Dermal pharmaceutical compositions of 1-methyl-2',6'-pipecoloxylidide and method of use
JP6086326B2 (ja) 2010-05-24 2017-03-01 ユニヴァーシティー オブ ロチェスター 二環式ヘテロアリールキナーゼ阻害剤および使用方法
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
EP2654757A1 (en) 2010-12-22 2013-10-30 Entarco SA The use of spinosyns and spinosyn compositions as local anesthetics and as antiarrhythmic agents
EP3502236B1 (en) 2011-02-18 2023-08-23 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
CN104884059B (zh) 2012-11-30 2018-08-10 罗切斯特大学 用于hiv/aids治疗的混合谱系激酶抑制剂
US9420820B2 (en) 2013-08-09 2016-08-23 University Of Tsukuba Method for isolating polyphenols from olive mill water
EP3119394B1 (en) 2014-03-19 2021-05-12 Curza Global LLC Compositions and methods comprising 2-(acylamino)imidazoles
JP2020512981A (ja) 2017-03-31 2020-04-30 カーザ グローバル，リミティド ライアビリティ カンパニー 置換２−アミノイミダゾールを含む組成物と方法
JP2021534196A (ja) 2018-08-23 2021-12-09 シージェン インコーポレイテッド 抗ｔｉｇｉｔ抗体
WO2022098972A1 (en) 2020-11-08 2022-05-12 Seagen Inc. Combination-therapy antibody drug conjugate with immune cell inhibitor
EP4320160A1 (en) 2021-04-09 2024-02-14 Seagen Inc. Methods of treating cancer with anti-tigit antibodies
WO2024191807A1 (en) 2023-03-10 2024-09-19 Seagen Inc. Methods of treating cancer with anti-tigit antibodies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3634016A1 (de) * 1986-04-17 1987-10-29 Lohmann Gmbh & Co Kg Flaechenfoermiges therapeutisches system, verfahren zu seiner herstellung und seine verwendung
US5211947A (en) * 1988-12-16 1993-05-18 Schering Corporation Method for lowering blood cholesterol levels with granulocyte-macrophage colony stimulating factor
US5316765A (en) * 1989-09-07 1994-05-31 Karl Folkers Foundation For Biomedical And Clinical Research Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies
ATE143603T1 (de) * 1990-03-30 1996-10-15 Yasunori Morimoto Transdermal absorbierbares mittel mit morphin hydrochlorid
IL109037A (en) * 1993-03-19 1999-01-26 Cellegy Pharma Inc Preparations for causing phase separation of lipid layers and preparation of the above preparations
DE4341444C2 (de) * 1993-12-04 1996-03-14 Lohmann Therapie Syst Lts Wirkstoffhaltiges Pflaster und Verfahren zu seiner Herstellung
US5968983A (en) * 1994-10-05 1999-10-19 Nitrosystems, Inc Method and formulation for treating vascular disease

Also Published As

Publication number Publication date
MY132407A (en) 2007-10-31
KR100445940B1 (ko) 2005-09-30
PT859595E (pt) 2000-04-28
AU716896B2 (en) 2000-03-09
JP2001507331A (ja) 2001-06-05
SK55898A3 (en) 1998-11-04
MX9803563A (es) 1998-09-30
CZ289143B6 (cs) 2001-11-14
DE19541260A1 (de) 1997-05-07
EP0859595B1 (de) 1999-11-03
CN1201385A (zh) 1998-12-09
GR3032523T3 (en) 2000-05-31
WO1997017061A1 (de) 1997-05-15
PL326497A1 (en) 1998-09-28
SK281405B6 (sk) 2001-03-12
NO982006D0 (no) 1998-05-04
ES2141534T3 (es) 2000-03-16
IL124279A (en) 2003-07-06
ATE186209T1 (de) 1999-11-15
NZ318783A (en) 1999-04-29
US6379696B1 (en) 2002-04-30
EP0859595A1 (de) 1998-08-26
ZA969271B (en) 1997-06-03
DE59603597D1 (de) 1999-12-09
KR19990067320A (ko) 1999-08-16
CZ136698A3 (cs) 1998-07-15
AU7085996A (en) 1997-05-29

Similar Documents

Publication Publication Date Title
NO982006L (no) Terapeutisk preparat for transdermal tilf°rsel av virksomme stoffer gjennom huden
AU3984597A (en) Formulation of 5-ht agonists
BR0312933A (pt) Composição farmacêutica, unidade de dosagem farmacêutica, método para tratar uma ou mais doenças associadas com uma condição vascular, e, combinação terapêutica
YU59098A (sh) Derivati spiro-piperidina, postupak njihovog dobijanja, njihova upotreba u proizvodnji leka korisnog za lečenje ili prevenciju bolova, upalnih procesa, migrene, povraćanja i postherpetične neuralgije i farmaceutski sastav koji ih sadrži
WO2001027119A3 (de) Substanzbibliothek enthaltend bicyclische imidazo-5-yl-amine und/oder bicyclische imidazo-3-yl-amine
AU4597796A (en) Steroid receptor modulator compounds and methods
TR200100922T2 (tr) Aktif maddelerin akciğerler yolu ile tatbik edilmesi.
AU3508497A (en) Androgen receptor modulator compounds and methods
PT1480634E (pt) Moduladores selectivos do receptor do androgénio (sarms) para o tratamento da hiperplasia benigna da próstata
AU2002342765A1 (en) Active ingredient combinations of polyhexamethylenebiguanidine hydrochloride and distearyldimethylammonium chloride and preparations comprising said active ingredient combinations
DE69727922D1 (de) Schnell zerfallende orale dosierungsform
WO2001001972A3 (en) SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
DK1063995T3 (da) Kombination til behandling af alkoholafhængighed indeholdende en opiod-antagonist og en NMDA-receptorkompleks-modulator
WO1999063976A3 (en) Liver-selective glucocorticoid antagonist for treating diabetes
DE69801660D1 (de) Lokale behandlung von psoriasis unter verwendung neutralisierender antikörper gegen il-8
EP0934065A4 (en) PHARMACEUTICAL COMPOSITION
EP1064966A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
PT855916E (pt) Composicao farmaceutica contendo um estimulador de activina ou inibina
AU1023497A (en) Tissue factor - kunitz domain fusion proteins as factor viia inhibitors
WO2002036129A3 (de) Topische behandlung von mastalgie mit aromatase-hemmern, wie androstendion
AU2002321232A1 (en) Treatment of hair follicle with neurokinin 1 receptor antagonists
WO2000001415A3 (en) Use of inhibitors of protein kinase c epsilon to treat pain
MX9601149A (es) Uso de un antagonista del peptido derivado del gen de calcitonina para el tratamiento del prurito y de las disestesias oculares o palpebrales y composicion que incluye dicho antagonista.
WO1999020244A3 (de) Verfahren zur transdermalen applikation von wirkstoffen in hoher, konstanter dosierung
FI962369A7 (fi) Farmaseuttinen formulointi myrkytyksen ehkäisemiseksi tai esihoidoksi organofosforisilla koliiniesteraasi-inhibiittoreilla

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application